文献速递衰弱、肌少症与跌倒老年慢病共病管理

骨骼肌计量对胃肠疾病老年患者肌少症的诊断价值

Diagnostic Value of Sarcopenia Computed Tomography Metrics for Older Patients with or without Cancers with Gastrointestinal Disorders.
PubMed 文献 · J Am Med Dir Assoc · 2022-12-02

这项前瞻性横断面研究纳入385例≥60岁胃肠疾病住院患者,比较CT图像中第12胸椎、第3腰椎、竖脊肌和腰大肌区域的肌肉指标与2019年亚洲肌少症工作组共识的相关性及诊断准确性。结果显示骨骼肌计量(SMG=SMI×SMD)在多个区域诊断准确性优于骨骼肌指数(SMI),且L3SMG与1年癌症相关死亡率独立相关。

要点

  • SMG与肌肉量的相关性优于SMD,与肌肉功能的相关性优于SMI。
  • L3SMG诊断准确性最高,AUC为0.87‒0.88,优于L3SMI的0.80‒0.82。
  • 仅L3SMG与1年癌症相关死亡率独立相关,相对风险为0.92。

核心结论

  • L3SMG涵盖肌少症的全部特征,诊断价值优于其他CT指标,可仅通过CT完成肌少症评估,且不限于癌症人群。

研究设计与样本

  • 前瞻性横断面研究,纳入385例年龄≥60岁、患有胃肠疾病且伴或不伴癌症的住院患者,中位年龄69.0岁,男性占60.8%。
  • 使用第12胸椎、第3腰椎、竖脊肌和腰大肌区域的CT图像指标与2019年亚洲肌少症工作组共识进行相关性分析,并用受试者工作特征曲线下面积(AUC)比较各指标差异。

关键数值与推荐

  • 以2019年亚洲肌少症工作组共识作为肌少症诊断参考标准。
  • 骨骼肌计量(SMG)定义为骨骼肌指数(SMI)乘以骨骼肌密度(SMD)。
  • L3SMG诊断肌少症的AUC为0.87‒0.88,L3SMI的AUC为0.80‒0.82。

临床怎么用

  • 对≥60岁胃肠疾病住院患者,可考虑采用L3水平的CT骨骼肌计量(SMG)评估肌少症,其诊断准确性优于传统SMI。
  • L3SMG与1年癌症相关死亡率独立相关,或可作为预后评估的参考指标。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The diagnostic utility of poor body composition measures in sarcopenia remains unclear. We hypothesize that the skeletal muscle gauge [combination of skeletal muscle index (SMI) and skeletal muscle density (SMD); SMG = SMI × SMD] would have significant diagnostic and predictive value in certain muscle regions and populations. DESIGN: Prospective cross-sectional study. SETTING AND PARTICIPANTS: We examined inpatients age ≥60 years with or without cancer and with gastrointestinal disorders. METHODS: We used computed tomography (CT) image metrics in the 12th thoracic (T12), third lumbar (L3), erector spinae muscle (ESM), and psoas muscle (PM) regions to establish correlations with the 2019 Asian Working Group for Sarcopenia Consensus and used receiver operating characteristic area under the curve (AUC) to compare differences between metrics. Associations between CT metrics and mortality were reported as relative risk after adjustments. RESULTS: We evaluated 385 patients (median age, 69.0 years; 60.8% men) and found consistent trends in cancer (49.6%) and noncancer (50.4%) cohorts. SMG had a stronger correlation with muscle mass than SMD [mean rho: 0.68 (range, 0.59‒0.73) vs 0.39 (range, 0.28‒0.48); all P < .01] in T12, L3, and PM regions and a stronger correlation with muscle function than SMI [mean rho: 0.60 (range, 0.50‒0.77) vs 0.36 (range, 0.22‒0.58); all P < .05] in T12, ESM, and L3 regions. SMG outperformed SMI in diagnostic accuracy in all regions, particularly for L3 (AUC: 0.87‒0.88 vs 0.80‒0.82; both P < .05). PMG (PM gauge) and L3SMG did not differ, whereas EMG (ESM gauge) or T12SMG and L3SMG did (AUC: 0.80‒0.82 vs 0.87‒0.88; all P < .05). L3SMI, L3SMD, T12SMG, EMG, and PMG showed no association with 1-year cancer-related mortality after adjusting for confounders; however, L3SMG [relative risk = 0.92 (0.85‒0.99); P = .023) was. CONCLUSIONS AND IMPLICATIONS: L3SMG covers all features of sarcopenia with more diagnostic value than other metrics, allowing a complete sarcopenia assessment with CT alone and not just in populations with cancer.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhang T, Yin W, et al. Diagnostic Value of Sarcopenia Computed Tomography Metrics for Older Patients with or without Cancers with Gastrointestinal Disorders. J Am Med Dir Assoc. 2022. PMID: 36463968. doi:10.1016/j.jamda.2022.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。